We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Amarin (AMRN) This Earnings Season?
Read MoreHide Full Article
Amarin Corporation PLC (AMRN - Free Report) is scheduled to report fourth-quarter 2019 results on Feb 25, after market close. In the last reported quarter, the company delivered a positive earnings surprise of 200.00%.
Notably, Amarin’s earnings history is decent. This pharmaceuticals company outpaced estimates in three out of the last four quarters and missed in one, with the average beat being 109.17%.
Shares of Amarin have outperformed the industry in the past year. The stock has gained 5.3% against the industry’s decrease of 2.7%.
Let’s see how things have shaped up for this announcement.
Factors to Note
Amarin’s Vascepa demonstrated solid sales on the back of strong demand and an expanded sales force promoting the drug in the first nine months of 2019. The drug is marketed as an adjunct to diet to reduce triglyceride levels in severe hypertriglyceridemia patients. We expect the momentum to have continued in the fourth quarter. The Zacks Consensus Estimate for product sales, primarily comprising Vascepa, stands at $133 million.
The company earns fees from its licensed partners related to commercialization of Vascepa outside the United States, which is expected to have increased in the soon-to-be-reported quarter. The Zacks Consensus Estimate for licensing revenues stands at $0.74 million.
In its preliminary results announced last month, the company maintained its revenue expectation for 2020 in the range of $650-$710 million, primarily from Vascepa sales, indicating growth of more than 50% year over year. It expects operating expense to increase approximately $200 to $250 million in 2020 from 2019 level mainly driven by increase in its sales team and various planned promotional programs related to Vascepa. We expect the company to provide an update on the guidance on its fourth-quarter earnings call.
In a major development, a regulatory application seeking Vascepa’s label expansion as an adjunct therapy to reduce cardiovascular risk based on data from REDUCE-IT cardiovascular outcomes study was approved by the FDA in December 2019. The company has been expanding its sales team to support the launch of Vascepa in the expanded label. We expect this activity to have driven operating expenses higher in the soon-to-be reported quarter.
Investor focus will be on updates on payer coverage for Vascepa and its launch in expanded patient population, expansion in Canada and Europe, and impact of competition from other approved drugs, especially Sanofi (SNY - Free Report) and Amgen’s (AMGN - Free Report) PCSK9 inhibitors, Praluent and Repatha, respectively on the fourth-quarter call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Amarin this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (loss of 2 cents) and the Zacks Consensus Estimate (earnings of 1 cent), stands at -399.99%.
Here is a biotech stock that you may want to consider, as our model shows that it has the right combination of elements to deliver an earnings beat in its upcoming release.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
What's in the Cards for Amarin (AMRN) This Earnings Season?
Amarin Corporation PLC (AMRN - Free Report) is scheduled to report fourth-quarter 2019 results on Feb 25, after market close. In the last reported quarter, the company delivered a positive earnings surprise of 200.00%.
Notably, Amarin’s earnings history is decent. This pharmaceuticals company outpaced estimates in three out of the last four quarters and missed in one, with the average beat being 109.17%.
Shares of Amarin have outperformed the industry in the past year. The stock has gained 5.3% against the industry’s decrease of 2.7%.
Let’s see how things have shaped up for this announcement.
Factors to Note
Amarin’s Vascepa demonstrated solid sales on the back of strong demand and an expanded sales force promoting the drug in the first nine months of 2019. The drug is marketed as an adjunct to diet to reduce triglyceride levels in severe hypertriglyceridemia patients. We expect the momentum to have continued in the fourth quarter. The Zacks Consensus Estimate for product sales, primarily comprising Vascepa, stands at $133 million.
The company earns fees from its licensed partners related to commercialization of Vascepa outside the United States, which is expected to have increased in the soon-to-be-reported quarter. The Zacks Consensus Estimate for licensing revenues stands at $0.74 million.
In its preliminary results announced last month, the company maintained its revenue expectation for 2020 in the range of $650-$710 million, primarily from Vascepa sales, indicating growth of more than 50% year over year. It expects operating expense to increase approximately $200 to $250 million in 2020 from 2019 level mainly driven by increase in its sales team and various planned promotional programs related to Vascepa. We expect the company to provide an update on the guidance on its fourth-quarter earnings call.
In a major development, a regulatory application seeking Vascepa’s label expansion as an adjunct therapy to reduce cardiovascular risk based on data from REDUCE-IT cardiovascular outcomes study was approved by the FDA in December 2019. The company has been expanding its sales team to support the launch of Vascepa in the expanded label. We expect this activity to have driven operating expenses higher in the soon-to-be reported quarter.
Investor focus will be on updates on payer coverage for Vascepa and its launch in expanded patient population, expansion in Canada and Europe, and impact of competition from other approved drugs, especially Sanofi (SNY - Free Report) and Amgen’s (AMGN - Free Report) PCSK9 inhibitors, Praluent and Repatha, respectively on the fourth-quarter call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Amarin this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (loss of 2 cents) and the Zacks Consensus Estimate (earnings of 1 cent), stands at -399.99%.
Zacks Rank: Amarin currently has a Zacks Rank #3.
Amarin Corporation PLC Price and Consensus
Amarin Corporation PLC price-consensus-chart | Amarin Corporation PLC Quote
A Stock That Warrants a Look
Here is a biotech stock that you may want to consider, as our model shows that it has the right combination of elements to deliver an earnings beat in its upcoming release.
AMAG Pharmaceuticals, Inc. has an Earnings ESP of +31.03% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>